Winquist Raymond J, Kwong Ann, Ramachandran Ravi, Jain Jugnu
Department of Pharmacology, Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, MA 02139, United States.
Biochem Pharmacol. 2007 Nov 1;74(9):1321-9. doi: 10.1016/j.bcp.2007.04.026. Epub 2007 May 3.
Multiple sclerosis is a demyelinating disease which is presumed to be a consequence of infiltrating lymphocytes autoreactive to myelin proteins. This is substantiated by several lines of clinical evidence and supported by correlative studies in preclinical models. The development of new therapeutics for MS has been guided by this perspective; however, the pathogenesis of MS has proven to be quite complex as observations exist which question the role of autoreactive lymphocytes in the etiology of MS. In addition the current immunomodulatory therapeutics do not prevent most patients from progressing into more serious forms of the disease. The development of truly transformational therapeutics for MS will likely require a broad assault that expands beyond the concept of MS being an autoimmune disease.
多发性硬化症是一种脱髓鞘疾病，据推测是对髓鞘蛋白具有自身反应性的浸润淋巴细胞所致。这得到了多方面临床证据的证实，并得到临床前模型相关研究的支持。MS新疗法的开发一直受这一观点的指导；然而，MS的发病机制已被证明相当复杂，因为有观察结果对自身反应性淋巴细胞在MS病因中的作用提出了质疑。此外，目前的免疫调节疗法并不能阻止大多数患者发展为更严重的疾病形式。开发真正具有变革性的MS疗法可能需要进行广泛的研究，而不仅仅局限于MS是一种自身免疫性疾病的概念。
